269 results match your criteria Current Radiopharmaceuticals [Journal]


PET/MRI in Neuroendocrine Tumours: Blessings and Curses.

Curr Radiopharm 2019 04 4. Epub 2019 Apr 4.

Vita-Salute San Raffaele University, Milan, Italy

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/171290/article
Publisher Site
http://dx.doi.org/10.2174/1874471012999190404151701DOI Listing
April 2019
4 Reads

Pre-feasibility Study for Establishing Radioisotope and Radiopharmaceutical Production Facilities in Developing Countries.

Curr Radiopharm 2019 Mar 28. Epub 2019 Mar 28.

Niowave Inc, 1012 N Walnut St, Lansing, 48906, MI. United States.

Background: A significant number of developing countries have no facilities producing medical radioisotopes.

Objective: In this paper we show that access to life-saving radioisotopes and radiopharmaceuticals and the geographical distribution of corresponding infrastructure is highly unbalanced worldwide.

Methods: We discuss the main issues which need to be addressed in order to establish the production of radioisotopes and radiopharmaceuticals, which are especially important for developing countries as newcomers in the field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190328164253DOI Listing

Synthesis of Deuterium Labeled 5, 5-Dimethyl-3-(α, α, α-trifluoro-4-nitro-m-tolyl) Hydantoin.

Curr Radiopharm 2019 ;12(1):82-87

Department of Chemistry, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur Dist 522502, India.

Objective: Stable and non-radioactive isotope labeled compounds gained significance in recent drug discovery and other various applications such as bio-analytical studies. The modern bioanalytical techniques can study the adverse therapeutic effects of drugs by comparing isotopically labeled internal standards. A well-designed labeled compound can provide high-quality information about the identity and quantification of drug-related compounds in biological samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666181130162731DOI Listing
January 2019
1 Read

Preface.

Curr Radiopharm 2019 ;12(1):1-3

Department of Biocatalysis and Isotope Chemistry Almac Sciences Almac House Craigavon, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187447101201190213112330DOI Listing
January 2019
1 Read

State of the art and recent developments of radiopharmaceuticals for pancreatic neuroendocrine tumors imaging.

Curr Radiopharm 2019 Mar 5. Epub 2019 Mar 5.

Division of Nuclear Medicine, European Institute of Oncology Via Ripamonti 435 20141 Milano. Italy.

Background: Neuroendocrine tumors (NETs) are relatively rare tumors, mainly originating from the digestive system, that tend to be slow growing and are often diagnosed when metastatized. Surgery is the sole curative option but is feasible only in a minority of patients. Among them, pancreatic neuroendocrine tumors (pancreatic NETs or pNETs) account for less than 5% of all pancreatic tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190306104450DOI Listing
March 2019
2 Reads

Gamma emitters in pancreatic endocrine tumors imaging in the PET era: is there a clinical space for 99mTc-peptides?

Curr Radiopharm 2019 Mar 1. Epub 2019 Mar 1.

Health and Development Section, Interuniversitary Research Center for Sustainable Development, Napoli-Roma. Italy.

Background: Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms, sporadic or familial, even being part of a syndrome. Their diagnosis is based on symptoms, hormonal disorders or may be fortuitous. The role of Nuclear Medicine is important, mainly because of the possibility of a theranostic strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190301122524DOI Listing
March 2019
16 Reads

Evaluation of the radioprotective effects of melatonin against ionizing radiation-induced muscle tissue injury.

Curr Radiopharm 2019 Feb 19. Epub 2019 Feb 19.

Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Science, International Campus, Tehran. Iran.

Background: Radiotherapy (RT) is a treatment method for cancer using ionizing radiation (IR). The interaction between IR with tissues produces free radicals that cause biological damages.As the largest organ in the human body, the skeletal muscles may be affected by detrimental effects of ionizing radiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190219120329DOI Listing
February 2019
2 Reads

Imaging of Pancreatic-Neuroendocrine Tumours: an Outline of Conventional Radiological Techniques.

Curr Radiopharm 2019 Feb 14. Epub 2019 Feb 14.

Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS. United Kingdom.

Introduction: Pancreatic neuroendocrine tumours (p-NETs) are an important disease entity and comprise of peptide-secreting tumours often with a functional syndrome. Accounting for a small percentage of all pancreatic tumours, they have a good overall survival rate when diagnosed early, with surgery being curative. The role of nuclear medicine in the diagnosis and treatment of these tumours is evident. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190214165845DOI Listing
February 2019
2 Reads

Physiopathological premises to Nuclear Medicine Imaging of pancreatic neuroendocrine tumours.

Curr Radiopharm 2019 Feb 5. Epub 2019 Feb 5.

Nuclear Medicine Unit, Department of Clinical and Experimental Medicine ''F.Magrassi, A.Lanzara'' - Università della Campania "Luigi Vanvitelli", Napoli. Italy.

Background: Pancreatic neuroendocrine tumors (P-NETs) are a challenge in terms of both diagnosis and therapy; morphological studies need to be frequently implemented with non standard techniques such as Endoscopic Ultrasounds , Dynamic CT, functional Magnetic Resonance.

Discussion: The role of nuclear medicine's, being scarcely sensitive F-18 Fluorodeoxyglucose, is mainly based on the over-expression of somatostatin receptors (SSTR) on neuroendocrine tumor cells surface. Therefore SSTR can be used as a target for both diagnosis, using radiotracers labeled with gamma or positron emitters, and therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190206094555DOI Listing
February 2019
1 Read

New 99mTc Radiotracers for Myocardial Perfusion Imaging by SPECT.

Authors:
Wei Fang Shuang Liu

Curr Radiopharm 2019 Feb 5. Epub 2019 Feb 5.

School of Health Sciences, Purdue University, IN 47907. United States.

Objective: Myocardial perfusion imaging (MPI) with radiotracers is an integral component in evaluation of the patients with known or suspected coronary artery diseases (CAD). 99mTc-Sestamibi and 99mTc-Tetrofosmin are commercial radiopharmaceuticals for MPI by single photon-emission computed tomography (SPECT). Despite their widespread clinical applications, they do not meet the requirements of an ideal perfusion imaging agent due to their inability to linearly track the regional myocardial blood flow rate at >2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190206102214DOI Listing
February 2019
4 Reads

Peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours.

Curr Radiopharm 2019 Feb 1. Epub 2019 Feb 1.

Department of Nuclear Medicine, Hammersmith Hospital, Imperial College NHS Trust, London. United Kingdom.

Background: The incidence of pancreatic neuroendocrine tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management.

Objective: The aim of this review is to investigate the outcome of Peptide Receptor Radionuclide Therapy (PRRT) in treatment of pancreatic neuroendocrine tumours. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190201164132DOI Listing
February 2019
23 Reads

Comparison between 18f-Dopa and 18f-Fet Pet/Ct in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and our Experience.

Curr Radiopharm 2019 01 15. Epub 2019 Jan 15.

Oncology 1 Unit, Veneto Institute of Oncology IOV - IRCCS, Padua. Italy.

Purposes: The aims of the present study were to: 1- critical assess the utility of L-3,4-dihydroxy-6-18Ffluoro-phenyl-alanine (18F-DOPA) and O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) positron emission tomography (PET)/computed tomography (CT) in patients with high grade glioma (HGG) and 2- describe the results of 18F-DOPA and 18F-FET PET/CT in a case series of patients with recurrent HGG.

Materials And Methods: We searched for studies using the following databases: PubMed, Web of Science and Scopus. The search terms were: glioma OR brain neoplasm and DOPA OR DOPA PET OR DOPA PET/CT and FET OR FET PET OR FET PET/CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190115124536DOI Listing
January 2019
1 Read

O‑(2‑[18F]‑fluoroethyl)-L‑tyrosine (FET) in neurooncology: A review of experimental results.

Curr Radiopharm 2019 Jan 10. Epub 2019 Jan 10.

Dept. of Nuclear Medicine, University of Aachen, Aachen. Germany.

Objectives: In recent years, PET using radiolabelled amino acids has gained considerable interest as an additional tool besides MRI to improve the diagnosis of cerebral gliomas and brain metastases. A very successful tracer in this field is O-(2-[18F]fluoroethyl)-L-tyrosine (FET) which in recent years has replaced short lived tracers such as [11C]-methyl-L-methionine in many neuro-oncological centers in Western Europe. FET can be produced with high efficiency and distributed in a satellite concept like 2-[18F]fluoro-2-deoxy-D-glucose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190111111046DOI Listing
January 2019
1 Read

Feasibility and evaluation of automated methods for radiolabeling of radiopharmaceutical kits with gallium-68.

Curr Radiopharm 2019 Jan 10. Epub 2019 Jan 10.

Hospices Civils de Lyon, Centre Hospitalier de Lyon Sud, Service de Pharmacie, unité de radiopharmacie, 165 Chemin du Grand Revoyet F-69310 Pierre-Bénite. France.

Objective: Recent gallium-68 labeled peptides are of increasing interest for PET imaging in nuclear medicine. Somakit TOC® is a radiopharmaceutical kit registered in the European Union for the preparation of [68Ga]Ga-DOTA-TOC used for the diagnosis of neuroendocrine tumors. Development of a labeling process using a synthesizer is particularly interesting for quality and reproducibility of the final product although only manual processes are described in the Summary of Product (SmPC) of the registered product. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666190110170623DOI Listing
January 2019
2 Reads

[F]Amylovis as a Potential PET Probe for β-Amyloid Plaque: Synthesis, In Silico, In vitro and In vivo Evaluations.

Curr Radiopharm 2019 ;12(1):58-71

Department of Neurochemistry, Cuban Center for Neurosciences, Havana, Cuba.

Background: Alzheimer's disease (AD) is the most common form of dementia. Neuroimaging methods have widened the horizons for AD diagnosis and therapy. The goals of this work are the synthesis of 2-(3-fluoropropyl)-6-methoxynaphthalene (5) and its [18F]-radiolabeled counterpart ([18F]Amylovis), the in silico and in vitro comparative evaluations of [18F]Amylovis and [11C]Pittsburg compound B (PIB) and the in vivo preclinical evaluation of [18F]Amylovis in transgenic and wild mice. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/168721/article
Publisher Site
http://dx.doi.org/10.2174/1874471012666190102165053DOI Listing
January 2019
6 Reads

[Ga]-Dota Peptide PET/CT in Neuroendocrine Tumors: Main Clinical Applications.

Curr Radiopharm 2019 ;12(1):11-22

Department of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy.

Objective: Neuroendocrine Neoplasms (NENs) are generally defined as rare and heterogeneous tumors. The gastrointestinal system is the most frequent site of NENs localization, however they can be found in other anatomical regions, such as pancreas, lungs, ovaries, thyroid, pituitary, and adrenal glands. Neuroendocrine neoplasms have significant clinical manifestations depending on the production of active peptide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666181212101244DOI Listing
January 2019
6 Reads

Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.

Curr Radiopharm 2019 ;12(1):4-10

Department of Radiation Oncology, University of Health Sciences, Gulhane Medical Faculty, Ankara, Turkey.

Background And Objective: Although accounting for a relatively small proportion of all lung cancers, small cell lung cancer (SCLC) remains to be a global health concern with grim prognosis. Radiotherapy (RT) plays a central role in SCLC management either as a curative or palliative therapeutic strategy. There has been considerable progress in RT of SCLC, thanks to improved imaging techniques leading to accurate target localization for precise delivery of RT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666181120162434DOI Listing
January 2019
15 Reads

Biochemical and Histopathological Evaluation of the Radioprotective Effects of Melatonin Against Gamma Ray-Induced Skin Damage.

Curr Radiopharm 2019 ;12(1):72-81

Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Background: Radiotherapy is one of the treatment methods for cancers using ionizing radiations. About 70% of cancer patients undergo radiotherapy. Radiation effect on the skin is one of the main complications of radiotherapy and dose limiting factor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471012666181120163250DOI Listing
January 2019
18 Reads

The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.

Curr Radiopharm 2018 ;11(3):154-155

Emeritus, Prorgam Manager, Corporate Fellow Nuclear Medicine Program Isotope Development Group Nuclear Security and Isotope Technology Division Oak Ridge National Laboratory (ORNL) P. O. Box 2008, 1 Bethel Valley Road Oak Ridge, TN, 37831-6229, United States.

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/165289/article
Publisher Site
http://dx.doi.org/10.2174/187447101103180911115600DOI Listing
January 2019
15 Reads

Synthesis of [F]FAZA Using Nosyl and Iodo Precursors for Nucleophilic Radiofluorination.

Curr Radiopharm 2019 ;12(1):49-57

Department of Oncology, University of Alberta, and Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta AB, Canada.

Background: 1-α-D-(5-Deoxy-5-[18F]fluoroarabinofuranosyl)-2-nitroimidazole ([18F]FAZA) is manufactured by nucleophilic radiofluorination of 1-α-D-(2',3'-di-O-acetyl-5'-O-toluenesulfonylarabinofuranosyl)- 2-nitroimidazole (DiAcTosAZA) and alkaline deprotection to afford [18F]FAZA. High yields (>60%) under optimized conditions frequently revert to low yields (<20%) in large scale, automated syntheses. Competing side reactions and concomitant complex reaction mixtures contribute to substantial loss of product during HPLC clean-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666181019105947DOI Listing
January 2019
2 Reads

Determination of Gamma Camera's Calibration Factors for Quantitation of Diagnostic Radionuclides in Simultaneous Scattering and Attenuation Correction.

Curr Radiopharm 2019 ;12(1):29-39

Isfahan University of Medical Sciences, P.O. Box: 8174673461, Isfahan, Iran.

Objective: The characterization of cancerous tissue and bone metastasis can be distinguished by accurate assessment of accumulated uptake and activity from different radioisotopes. The various parameters and phenomena such as calibration factor, Compton scattering, attenuation and penetration intrinsicallyinfluence calibration equation, and the qualification of images as well.

Methods: The camera calibration factor (CF) translates reconstructed count map into absolute activity map, which is determined by both planar and tomographic scans using different phantom geometries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180914095222DOI Listing
January 2019
3 Reads

Evaluating the Radioprotective Effect of Curcumin on Rat's Heart Tissues.

Curr Radiopharm 2019 ;12(1):23-28

Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences (International Campus), Tehran, Iran.

Background: Heart injury is one of the most important concerns after exposure to a high dose of radiation in chest cancer radiotherapy or whole body exposure to a radiation disaster. Studies have proposed that increased level of inflammatory and pro-fibrotic cytokines following radiotherapy or radiation events play a key role in the development of several side effects such as cardiovascular disorders. In the current study, we aimed to evaluate the expression of IL-4 and IL-13 cytokines as well as signaling pathways such as IL4Ra1, IL13Ra2, Duox1 and Duox2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180831101459DOI Listing
January 2019
7 Reads

Dosimetry and Toxicity Studies of the Novel Sulfonamide Derivative of Sulforhodamine 101([18F]SRF101) at a Preclinical Level.

Curr Radiopharm 2019 ;12(1):40-48

Uruguayan Centre of Molecular Imaging (CUDIM), Radiopharmacy Department, Montevideo, Uruguay.

Background: The SR101 N-(3-[18F]Fluoropropyl) sulfonamide ([18F]SRF101) is a Sulforhodamine 101 derivative that was previously synthesised by our group. The fluorescent dye SR101 has been reported as a marker of astroglia in the neocortex of rodents in vivo.

Objective: The aim of this study was to perform a toxicological evaluation of [18F]SRF101 and to estimate human radiation dosimetry based on preclinical studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180830145304DOI Listing
January 2019
12 Reads

Choline-PET/CT in the Differential Diagnosis Between Cystic Glioblastoma and Intraparenchymal Hemorrhage.

Curr Radiopharm 2019 ;12(1):88-92

Neurorehabilitation Unit, Department of Rehabilitation, Fondazione Istituto G. Giglio, Cefalu, Italy.

Objective: Glioblastoma multiforme (GBM) represents the most common and malignant glioma, accounting for 45%-50% of all gliomas. The median survival time for patients with glioblastoma is only 12-15 months after surgical, chemioterapic and radiotherapic treatment; a correct diagnosis is naturally fundamental to establish a rapid and correct therapy. Non-invasive imaging plays a pivotal role in each phase of the diagnostic workup of patients with suspected for diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180817122427DOI Listing
January 2019
18 Reads

Stability Study of [18F]Fludeoxyglucose and [18F]Fluorocholine in Different Medical Devices for Intravenous Administration.

Curr Radiopharm 2018 ;11(2):138-146

Pharmacy Department, Radiopharmacy Unit, Hospices Civils de Lyon, Lyon Sud Hospital, 165 Chemin du Grand Revoyet F-69310 Pierre-Benite, France.

Objective: The present study had determine the impact of prolonged storage in a cartridge or syringe on the quality of the [18F]-radiopharmaceuticals used in our center [18F]fludeoxyglucose and [18F]fluorocholine). [18F]-radiopharmaceuticals registered as ready-to-use drugs are prepared in multidose flasks. When the change of packaging must be made extemporaneously for the preparation of patient unit doses in a syringe or cartridge, this is under the responsibility of radiopharmacists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180703165639DOI Listing
October 2018
15 Reads

Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.

Curr Radiopharm 2018 ;11(2):147-152

Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States.

Background: 223Ra was the first therapeutic alpha-emitting radionuclide registered for clinical practice. This radionuclide is targeting actively bone-forming cells, and it is approved for treating metastatic skeletal disease in prostate cancer. 18F-PET is used to detect skeletal metastatic disease based on osteoblastic activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180629145030DOI Listing
October 2018
28 Reads

Evaluation of [Ac]Ac-DOTA for α-Therapy of Bone Metastases.

Curr Radiopharm 2018 ;11(3):223-230

Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany.

Background: Conjugates of bisphosphonates with macrocyclic chelators possess high potential in bone targeted radionuclide imaging and therapy. DOTAZOL, zoledronic acid conjugated to DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), demonstrated promising results in vivo in small animals as well as in first patient applications using 68Ga for diagnosis via PET and the lowenergy β-emitter 177Lu for therapy of painful bone metastases. In consideration of the fact that targeted α-therapy probably offers various advantages over the use of β--emitters, the 225Ac-labelled derivative [225Ac]Ac-DOTAZOL was synthesized and evaluated in vivo. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/162704/article
Publisher Site
http://dx.doi.org/10.2174/1874471011666180604083911DOI Listing
January 2019
10 Reads

Development and Evaluation of Liquid and Solid Lipid Based Drug Delivery Systems Containing Technetium-99m-Radiolabeled Alendronate Sodium.

Curr Radiopharm 2018 ;11(2):100-108

Ege University, Faculty of Pharmacy, Department of Radiopharmacy, 35100 Bornova, Izmir, Turkey.

Objective: The purpose of this study was to develop lipid-water based drug delivery system of Alendronate Sodium (ALD) in liquid and solid form obtained by using spray drying method and compare these two forms with radioactive cell culture studies.

Methods: This study included the development of liquid and solid form obtained by spray drying method, radiolabelling of ALD with 99mTc, preparation of formulations containing 99mTc -ALD and evaluation of their permeability with Caco-2 cell. The liquid formulations have been developed by using various surfactants, co-surfactants, oil and water phases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180529111914DOI Listing
October 2018
18 Reads

Radioprotective Effect of Cerium Oxide Nanoparticles Against Genotoxicity Induced by Ionizing Radiation on Human Lymphocytes.

Curr Radiopharm 2018 ;11(2):109-115

Department of Radiopharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran.

Background: Ionizing radiation induces DNA damage on normal cell results in apoptosis and cell deaths.

Objectives: The radioprotective effects of cerium oxide nanoparticles (CNPs) on genotoxicity, apoptosis and necrosis induced by Ionizing Radiation (IR) in human healthy lymphocytes as highly radiosensitive cells were investigated.

Materials And Methods: Lymphocytes were prepared from three volunteers and then treated with CNPs at different concentrations and exposed to IR at dose 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180528095203DOI Listing
October 2018
8 Reads

PET Evaluation of Late Cerebral Effect in Advanced Radiation Therapy Techniques for Cranial Base Tumors.

Curr Radiopharm 2018 ;11(2):86-91

Vita-Salute San Raffaele University and Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milano, Italy.

Background And Objective: Even though the benefits of radiation therapy are well established, it is important to recognize the broad spectrum of radiation-induced changes, particularly in the central nervous system. The possible damage to the brain parenchyma may have clinical consequences and in particular cognitive impairment might be one of the major complications of radiotherapy. To date, no studies have investigated the effects of focal radiation therapy on brain structure and function together with the assessment of their clinical outcomes at a long follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180525134301DOI Listing
October 2018
2 Reads

Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.

Authors:
Joseph G Jurcic

Curr Radiopharm 2018 ;11(3):192-199

Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, New York- Presbyterian Hospital, Herbert Irving Comprehensive Cancer Center, New York, NY, United States.

Objectives: Due to the shorter range and higher linear energy transfer of α-particles compared to β-particles, targeted α-particle therapy may produce more efficient tumor killing while sparing neighboring healthy cells. We will review the clinical studies using α-particle therapy for Acute Myeloid Leukemia (AML).

Methods: A series of clinical trials were conducted to assess the safety, feasibility, and anti-leukemic effects of lintuzumab, an anti-CD33 humanized monoclonal antibody, labeled with the α-emitters bismuth- 213 (213Bi) and actinium-225 (225Ac). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180525102814DOI Listing
January 2019
1 Read

NorthStar Perspectives for Actinium-225 Production at Commercial Scale.

Authors:
James T Harvey

Curr Radiopharm 2018 ;11(3):180-191

NorthStar Medical Technologies, LLC, Beloit, WI, United States.

Objective: Actinium-225, and its daughter Bismuth-213, have great promise in Alpha Immuno Therapy (AIT) for treatment of various disease modalities. Unfortunately, current production levels of actinium-225 do not support broad use of either actinium-225 or bismuth-213 in development or use for disease treatment. Further, the current cost per millicurie is much too high to be sustainable long term. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180515123848DOI Listing
January 2019
9 Reads

Automated Synthesis of 68Ga-DOTA-TOC with a Cationic Purification System: Evaluation of Methodological and Technical Aspects in Routine Preparations.

Curr Radiopharm 2018 ;11(2):130-137

Nuclear Medicine Unit, University Hospital, Ferrara (FE), Italy.

Background And Objective: Gallium-68 is a PET isotope available in each nuclear medicine departments, even those not equipped with a cyclotron, since it is easily obtained by eluting compact and transportable generator system. The preparation of Ga-68 DOTA-labeled compounds is performed by remotely controlled automated systems developed in order to ensure production efficiency, reproducibility of the results, fast reaction time, to facilitate the synthesis and minimize the radiation exposure. Many automatic synthesis systems are available on the radiopharmaceutical market, however, they requires some technical adaptations for routine use. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/161984/article
Publisher Site
http://dx.doi.org/10.2174/1874471011666180509101420DOI Listing
October 2018
32 Reads

An Overview of Targeted Alpha Therapy with Actinium and Bismuth.

Curr Radiopharm 2018 ;11(3):200-208

European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.

Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.

Objective And Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180502104524DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237921PMC
January 2019
20 Reads

Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides.

Curr Radiopharm 2018 ;11(3):209-214

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States.

Background: Radiopharmaceutical therapy is a cancer treatment modality by which radiation is delivered directly to targeted tumor cells or to their microenvironment. This makes it possible to deliver highly potent alpha-particle radiation. The short-range and highly potent nature of alpha-particles require a dosimetry methodology that considers microscale distributions of the alpha-emitting agent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180426130058DOI Listing
January 2019
4 Reads

Evaluation of Free and Chelated Accelerator-produced Actinium- 225 - Radiation Dosimetry and Toxicity Results.

Curr Radiopharm 2018 ;11(3):215-222

College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Rd, Health Sciences Bld, Box 3D01-11, Saskatoon, Saskatchewan, University of Saskatchewan, Saskatoon, SK, S7N 5E5, Canada.

Background And Objective: The demand for the alpha-emitting radionuclide Actinium-225 (225Ac) for use in radionuclide therapy is growing. Producing 225Ac using high energy linear accelerators, cyclotrons or photoinduction could increase its supply. One potential problem with accelerator produced 225Ac using Thorium-232 targets is the presence in final product of 0. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/161485/article
Publisher Site
http://dx.doi.org/10.2174/1874471011666180423120707DOI Listing
January 2019
10 Reads

Motion Management in PET/CT: Technological Solutions.

Curr Radiopharm 2018 ;11(2):79-85

Nuclear Medicine Department, San Gerardo Hospital, ASST-Monza, Italy.

Background And Objective: Motion due to patient's breathing can introduce heavy bias in PET/CT, both in image quality and quantitation. This paper is a review of the main technical solutions available to manage movement in PET/CT studies: a) Respiratory Gated (RG), b) Motion Free (MF), c) End Expiration (EE), d) Banana Artefact Management (BAM) and e) Data Driven Gating (DDG).

Methods: The most diffused solutions (RG, MF and EE) are based on LIST mode acquisition of a PET Field of View (4D FOV), centered on the anatomical region of interest; to link PET data not only to time and to spatial position but also to the corresponding breathing phase, the synchronized acquisition of the patient's breathing curve is performed by an external tracking device. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180419150440DOI Listing
October 2018
12 Reads

The Production of Ac-225.

Authors:
Jonathan W Engle

Curr Radiopharm 2018 ;11(3):173-179

Department of Medical Physics, University of Wisconsin, Madison, Wisconsin, United States.

Background: The radionuclide 225Ac and its daughter 213Bi are among the most interesting alpha emitters being evaluated for incorporation into targeted therapeutic vectors. Global supply of 225Ac is presently insufficient to meet anticipated clinical demand, but the deficiency has been targeted by many research and development efforts, privately and publicly funded. From more than a decade of these endeavors, no single production technology has emerged as a complete solution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180418141357DOI Listing
January 2019
5 Reads

Ga-68 Nanoparticles and Ultra-small Nanoparticle: Next Generation of PET Radiopharmaceuticals?

Curr Radiopharm 2018 ;11(2):123-129

Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil.

Background And Objective: The future of medicine relies on the capability to forecast the future and in the development of new drugs. The same rationale is applied to radiopharmacy. In this direction the development of nano-radiopharmaceuticals represents the most effective glance of the future. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180418110206DOI Listing
October 2018
13 Reads

Development of Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences.

Curr Radiopharm 2018 ;11(3):156-172

Life Sciences Division, TRIUMF, Vancouver BC, Canada.

Background: The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide.

Objectives: Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges that must be overcome to realize the widespread clinical use of 225Ac. Some of these challenges include the limited availability of the isotope, the challenging chemistry required to isolate 225Ac from any co-produced isotopes, and the need for stable targeting systems with high radiolabeling yields. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180416161908DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249690PMC
January 2019
22 Reads

Preparation and Dosimetry Evaluation of a Carrier- Free 90Y Labeled DOTMP as a Promising Agent for Bone Marrow Ablation.

Curr Radiopharm 2018 ;11(2):116-122

Nuclear Science and Technology Research Institute (NSTRI), P.O. Box: 11365-8486, Tehran, Iran.

Background And Objective: Skeletal uptake of 90Y-1,4,7,10-tetraazacyclododecane-1,4,7,10- tetramethylene-phosphonate (DOTMP) is used to deliver high doses of this radiopharmaceutical to the bone marrow.

Methods: In this research, carrier-free (c.f. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180412165722DOI Listing
October 2018
9 Reads

Modeling of a Cyclotron Target for the Production of 11C with Geant4.

Curr Radiopharm 2018 ;11(2):92-99

Medical Physics Unit, University Hospital "S. Orsola-Malpighi", Via Massarenti 9, 40138, Bologna, Italy.

Background: In medical cyclotron facilities, 11C is produced according to the 14N(p,α)11C reaction and widely employed in studies of prostate and brain cancers by Positron Emission Tomography. It is known from literature that the 11C-target assembly shows a reduction in efficiency during time, meaning a decrease of activity produced at the end of bombardment. This effect might depend on aspects which are still not completely known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180412170219DOI Listing
October 2018
11 Reads

Preface.

Curr Radiopharm 2018 ;11(1):2-3

Department of Biocatalysis and Isotope Chemistry Almac Sciences Almac House Craigavon, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187447101101180404093206DOI Listing
August 2018
4 Reads

Preliminary Human Radiation Dose Estimates of PET Renal Agents, Para-F-Fluorohippuric Acid and Ortho-I-Iodohippuric Acid from Rat Biodistribution Data.

Curr Radiopharm 2018 ;11(1):58-63

Department of Pharmaceutical Sciences, College of Pharmacy, the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.

Background: Para-18F-fluorohippuric acid (18F-PFH) and ortho-124I-iodohippuric acid (124IOIH) were recently identified as potential radiotracers suitable for conducting renography using positron emission tomography (PET). The aim of this work was to estimate preliminary human-equivalent internal radiation dose of 18F-PFH and 124I-OIH using the biodistribution data reported in healthy rats. The results were compared with the absorbed dose data of technetium-99m-mercaptoacetyltriglycine (99mTc- MAG3) as documented in the International Commission on Radiological Protection (ICRP) publication 80. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180212123534DOI Listing
August 2018
14 Reads

Quantification of Radiation Exposure of Non-Dominant Index for the Surgeon Performing Sentinel Lymph-Node Removal Procedure.

Curr Radiopharm 2018 ;11(1):64-68

Department of Nuclear Medicine, Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.

Background: Sentinel lymph-node scintigraphy is a useful method for accurate staging of different tumors and a helpful tool in personalized therapy for oncological patients. The radiation exposure for surgical staff has been a concern since the sentinel lymph-node detection method was developed.

Objective: The objective of the study was to determine and quantify the exposure to radiation of the non-dominant index for the surgeon performing sentinel lymph-node removal and to determine, if there is an irradiation risk imposed during the surgical procedure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666180206165744DOI Listing
August 2018
13 Reads

Mechanisms of Radiation Bystander and Non-Targeted Effects: Implications to Radiation Carcinogenesis and Radiotherapy.

Curr Radiopharm 2018 ;11(1):34-45

Scientific Research Department, Uniformed Services University of Health Sciences (USUHS), Armed Forces Radiobiology Research Institute (AFRRI), Bethesda, MD, 20889-5603, United States.

Background: Knowledge of radiobiology is of paramount importance to be able to grasp and have an in-depth understanding of the consequences of ionizing radiation. One of the most important effects of this physical stressor's interaction to targeted and non-targeted cells, tissues and organs is on the late effects on the development of primary and secondary cancers. Thus, an in-depth understanding of the mechanisms of radiation carcinogenesis remains to be elucidated, and some studies have demonstrated or proposed a role of non-targeted effect in excess risk of cancer incidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666171229123130DOI Listing
August 2018
23 Reads

Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.

Curr Radiopharm 2018 ;11(1):14-21

The Hospital for Sick Children, Division of Pediatric Hematology Oncology, University of Toronto, Toronto, Canada.

Background: Childhood neuroblastoma is a heterogenous disease with varied clinical presentation and biology requiring different approaches to investigation and management. Metaiodobenzylguanidine (MIBG) is an essential component of metastatic staging for neuroblastoma and has been used as a treatment strategy for relapsed and refractory neuroblastoma. However, as 10% of children with neuroblastoma will have 123I-MIBG non-avid imaging and up to 60% with relapsed and refractory neuroblastoma will require further treatment with 131I-MIBG, alternative radioisotopes have been investigated for imaging and treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666171215093112DOI Listing
August 2018
16 Reads

Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings.

Curr Radiopharm 2018 ;11(1):22-33

Sapienza University of Rome, Department of Radiology, Oncology and Human Pathology, Nuclear Medicine Unit, Rome, Italy.

Background: Positron emission tomography (PET) is an instrumental diagnostic modality developed around the positron-emitting radioisotopes of biologically important elements such as carbon, oxygen and nitrogen (11C, 15O, 13N). Among longer-lived PET radionuclides, 18F is by far the most commonly used radiotracer, extensively used for tumour imaging with FDG ([18F]-fluorodeoxyglucose) and also frequently investigated in the development of novel radiopharmaceuticals. Many other positron- emitting radionuclides with higher atomic numbers and longer half-lives have been investigated for both imaging and therapeutic purposes, including the halogens (124I, 120I, 76Br) and a number of metal radionuclides. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666171211161851DOI Listing
August 2018
12 Reads

PET Radiopharmaceuticals in Brazil and Belarus: Economic Comparison Using the Case of FDG.

Curr Radiopharm 2018 ;11(1):69-72

Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rua Helio de Almeida, 75, Ilha do Fundao, 21941906, Rio de Janeiro, Brazil.

Background: The production of radiopharmaceuticals, especially the PET ones, is a complex combination of economic and social factors. Despite the social aspects, that are essential, the economic issue must be considered and play an important parameter for the implementation and maintenance of producer centers around the world, with especial regards for countries which face economic crisis and/or belongs to aegis of under development countries.

Objectives: In order to evaluate this scenario with carried out this study, comparing a well-established producer center in Brazil and a new on in Belarus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471011666171211164111DOI Listing
August 2018
12 Reads